IPO registrations (S-1, F-1) · Registrants
GridAI Technologies Corp.
- SEC CIK
- 1604191 · filings on EDGAR ↗
- Former names
- Entero Therapeutics, Inc. (2024–2025); First Wave BioPharma, Inc. (2021–2024); AzurRx BioPharma, Inc. (2014–2021); BioPharma d'Azur, Inc. (2014–2014)
- Registration
- Form S-1, first filed 2016-07-13, last 2026-10-06; 10 initial registrations, 23 amendments
- Outcome
- Final prospectus filed 2016-10-13; declared effective 2016-10-11; withdrawal requested 2017-10-31
- Industry (SIC)
- Electric & Other Services Combined 4931
- Incorporated in
- DE
- Business address
- 433 PLAZA REAL, SUITE 275, Boca Raton, FL
- EIN
- 46-4993860
- Ticker
- GRDX (Nasdaq)
- EDGAR entity type
- operating
- Insiders and CEO pay
- GridAI Technologies Corp. on the corporate pages
On this site
- Business registration: FIRST WAVE BIOPHARMA, INC. EXACT (EIN (EXACT, as the state registration reports it))
- Form 5500 plan sponsor: ENTERO THERAPEUTICS, INC. EXACT (EIN (EXACT))
- Form D issuer: GridAI Technologies Corp. EXACT (CIK (EXACT))
- SEC filer: AzurRx BioPharma, Inc. EXACT (CIK (EXACT))
Filings 64
| Filed | Form | What it is | Name as filed | EDGAR |
|---|---|---|---|---|
| 2016-07-13 | S-1 | S-1 (registration) | AzurRx BioPharma, Inc. | 0001415889-16-006483 ↗ |
| 2016-07-29 | S-1/A | S-1/A (amendment) | AzurRx BioPharma, Inc. | 0001415889-16-006616 ↗ |
| 2016-08-05 | S-1/A | S-1/A (amendment) | AzurRx BioPharma, Inc. | 0001415889-16-006694 ↗ |
| 2016-08-09 | S-1/A | S-1/A (amendment) | AzurRx BioPharma, Inc. | 0001415889-16-006739 ↗ |
| 2016-09-06 | S-1/A | S-1/A (amendment) | AzurRx BioPharma, Inc. | 0001415889-16-007040 ↗ |
| 2016-09-19 | S-1/A | S-1/A (amendment) | AzurRx BioPharma, Inc. | 0001654954-16-002254 ↗ |
| 2016-10-05 | S-1/A | S-1/A (amendment) | AzurRx BioPharma, Inc. | 0001654954-16-002634 ↗ |
| 2016-10-11 | EFFECT | EFFECT (declared effective) | AzurRx BioPharma, Inc. | 9999999995-16-005935 ↗ |
| 2016-10-13 | 424B4 | 424B4 (final prospectus) | AzurRx BioPharma, Inc. | 0001654954-16-002783 ↗ |
| 2017-07-21 | S-1 | S-1 (registration) | AzurRx BioPharma, Inc. | 0001654954-17-006580 ↗ |
| 2017-08-09 | S-1/A | S-1/A (amendment) | AzurRx BioPharma, Inc. | 0001654954-17-007098 ↗ |
| 2017-08-11 | EFFECT | EFFECT (declared effective) | AzurRx BioPharma, Inc. | 9999999995-17-002100 ↗ |
| 2017-10-31 | RW | RW (withdrawal request) | AzurRx BioPharma, Inc. | 0001654954-17-009854 ↗ |
| 2017-11-17 | EFFECT | EFFECT (declared effective) | AzurRx BioPharma, Inc. | 9999999995-17-003015 ↗ |
| 2018-07-12 | EFFECT | EFFECT (declared effective) | AzurRx BioPharma, Inc. | 9999999995-18-001784 ↗ |
| 2019-06-07 | EFFECT | EFFECT (declared effective) | AzurRx BioPharma, Inc. | 9999999995-19-001307 ↗ |
| 2019-06-25 | EFFECT | EFFECT (declared effective) | AzurRx BioPharma, Inc. | 9999999995-19-001439 ↗ |
| 2019-12-31 | S-1 | S-1 (registration) | AzurRx BioPharma, Inc. | 0001654954-19-014339 ↗ |
| 2020-01-13 | S-1/A | S-1/A (amendment) | AzurRx BioPharma, Inc. | 0001654954-20-000383 ↗ |
| 2020-01-14 | EFFECT | EFFECT (declared effective) | AzurRx BioPharma, Inc. | 9999999995-20-000092 ↗ |
| 2020-09-17 | RW | RW (withdrawal request) | AzurRx BioPharma, Inc. | 0001654954-20-010208 ↗ |
| 2020-09-21 | EFFECT | EFFECT (declared effective) | AzurRx BioPharma, Inc. | 9999999995-20-002515 ↗ |
| 2021-01-13 | S-1 | S-1 (registration) | AzurRx BioPharma, Inc. | 0001654954-21-000392 ↗ |
| 2021-01-21 | EFFECT | EFFECT (declared effective) | AzurRx BioPharma, Inc. | 9999999995-21-000229 ↗ |
| 2021-02-16 | EFFECT | EFFECT (declared effective) | AzurRx BioPharma, Inc. | 9999999995-21-000665 ↗ |
| 2021-04-08 | EFFECT | EFFECT (declared effective) | AzurRx BioPharma, Inc. | 9999999995-21-001354 ↗ |
| 2021-06-02 | EFFECT | EFFECT (declared effective) | AzurRx BioPharma, Inc. | 9999999995-21-002190 ↗ |
| 2022-02-02 | EFFECT | EFFECT (declared effective) | First Wave BioPharma, Inc. | 9999999995-22-000307 ↗ |
| 2022-08-04 | EFFECT | EFFECT (declared effective) | First Wave BioPharma, Inc. | 9999999995-22-002262 ↗ |
| 2022-09-14 | S-1 | S-1 (registration) | First Wave BioPharma, Inc. | 0001104659-22-100084 ↗ |
| 2022-09-22 | S-1/A | S-1/A (amendment) | First Wave BioPharma, Inc. | 0001104659-22-102184 ↗ |
| 2022-10-06 | S-1/A | S-1/A (amendment) | First Wave BioPharma, Inc. | 0001104659-22-106780 ↗ |
| 2022-10-06 | EFFECT | EFFECT (declared effective) | First Wave BioPharma, Inc. | 9999999995-22-002970 ↗ |
| 2022-10-11 | 424B4 | 424B4 (final prospectus) | First Wave BioPharma, Inc. | 0001104659-22-107444 ↗ |
| 2022-12-08 | EFFECT | EFFECT (declared effective) | First Wave BioPharma, Inc. | 9999999995-22-003495 ↗ |
| 2023-03-27 | EFFECT | EFFECT (declared effective) | First Wave BioPharma, Inc. | 9999999995-23-000684 ↗ |
| 2023-06-05 | S-1 | S-1 (registration) | First Wave BioPharma, Inc. | 0001104659-23-067826 ↗ |
| 2023-06-27 | EFFECT | EFFECT (declared effective) | First Wave BioPharma, Inc. | 9999999995-23-001866 ↗ |
| 2023-07-07 | S-1/A | S-1/A (amendment) | First Wave BioPharma, Inc. | 0001104659-23-078875 ↗ |
| 2023-07-12 | S-1/A | S-1/A (amendment) | First Wave BioPharma, Inc. | 0001104659-23-080090 ↗ |
| 2023-07-13 | S-1/A | S-1/A (amendment) | First Wave BioPharma, Inc. | 0001104659-23-080564 ↗ |
| 2023-07-17 | EFFECT | EFFECT (declared effective) | First Wave BioPharma, Inc. | 9999999995-23-002106 ↗ |
| 2023-07-20 | 424B4 | 424B4 (final prospectus) | First Wave BioPharma, Inc. | 0001104659-23-082794 ↗ |
| 2023-09-29 | EFFECT | EFFECT (declared effective) | First Wave BioPharma, Inc. | 9999999995-23-002911 ↗ |
| 2023-11-03 | S-1 | S-1 (registration) | First Wave BioPharma, Inc. | 0001104659-23-114334 ↗ |
| 2023-12-18 | S-1/A | S-1/A (amendment) | First Wave BioPharma, Inc. | 0001104659-23-126525 ↗ |
| 2023-12-27 | S-1/A | S-1/A (amendment) | First Wave BioPharma, Inc. | 0001104659-23-129494 ↗ |
| 2023-12-28 | RW | RW (withdrawal request) | First Wave BioPharma, Inc. | 0001104659-23-129972 ↗ |
| 2024-01-17 | EFFECT | EFFECT (declared effective) | First Wave BioPharma, Inc. | 9999999995-24-000141 ↗ |
| 2024-06-10 | EFFECT | EFFECT (declared effective) | Entero Therapeutics, Inc. | 9999999995-24-001807 ↗ |
| 2025-05-12 | S-1 | S-1 (registration) | Entero Therapeutics, Inc. | 0001104659-25-047285 ↗ |
| 2025-06-05 | S-1/A | S-1/A (amendment) | Entero Therapeutics, Inc. | 0001104659-25-056916 ↗ |
| 2025-06-23 | S-1/A | S-1/A (amendment) | Entero Therapeutics, Inc. | 0001104659-25-061668 ↗ |
| 2025-07-02 | S-1/A | S-1/A (amendment) | Entero Therapeutics, Inc. | 0001104659-25-065403 ↗ |
| 2025-08-26 | S-1 | S-1 (registration) | Entero Therapeutics, Inc. | 0001104659-25-083105 ↗ |
| 2025-09-10 | S-1/A | S-1/A (amendment) | Entero Therapeutics, Inc. | 0001104659-25-089120 ↗ |
| 2025-09-15 | EFFECT | EFFECT (declared effective) | Entero Therapeutics, Inc. | 9999999995-25-002964 ↗ |
| 2026-03-17 | RW | RW (withdrawal request) | GridAI Technologies Corp. | 0001104659-26-028766 ↗ |
| 2026-05-28 | S-1 | S-1 (registration) | GridAI Technologies Corp. | 0001104659-26-067071 ↗ |
| 2026-07-09 | S-1/A | S-1/A (amendment) | GridAI Technologies Corp. | 0001104659-26-082306 ↗ |
| 2026-07-31 | S-1/A | S-1/A (amendment) | GridAI Technologies Corp. | 0001104659-26-089198 ↗ |
| 2026-08-24 | S-1/A | S-1/A (amendment) | GridAI Technologies Corp. | 0001104659-26-100274 ↗ |
| 2026-10-06 | S-1/A | S-1/A (amendment) | GridAI Technologies Corp. | 0001104659-26-114071 ↗ |
| 2026-10-19 | EFFECT | EFFECT (declared effective) | GridAI Technologies Corp. | 9999999995-26-003286 ↗ |
Officers, directors and large holders Forms 3, 4 and 5
| Insider | Role | Title | Filings | Years | On this site |
|---|---|---|---|---|---|
| BALK MATTHEW | TenPercentOwner | 4 | 2016–2017 | ||
| BORKOWSKI EDWARD | Director | 25 | 2016–2026 | ||
| Dupret Daniel | Officer | Chief Scientific Officer; CHIEF SCIENTIFIC OFFICER | 2 | 2016–2018 | |
| Pelican Partners LLC | TenPercentOwner | 4 | 2016–2017 | ||
| Riddell Alastair | Director | 20 | 2016–2024 | ||
| Ross Edmund Burke Jr. | TenPercentOwner | 6 | 2016–2020 | ||
| Shenouda Maged | Director; Director,Officer | CHIEF FINANCIAL OFFICER | 6 | 2016–2019 | |
| Spoor Johan M. | Director; Director,Officer | President and CEO; PRESIDENT AND CEO | 6 | 2016–2020 | |
| CASAMENTO CHARLES J | Director | 22 | 2017–2024 | ||
| Schramm Vern Lee | Director | 16 | 2017–2022 | ||
| Pennington James | Officer | Chief Medical Officer; CHIEF MEDICAL OFFICER | 6 | 2018–2022 | |
| SAPIRSTEIN JAMES | Director,Officer | Chairman and CEO; Chairman, President and CEO; PRES, CEO & CHAIRMAN OF BOARD; President and CEO; PRESIDENT AND CEO | 14 | 2019–2024 | |
| Schneiderman Daniel H | Officer | CHIEF FINANCIAL OFFICER | 5 | 2020–2022 | |
| Oakes Gregory | Director | 4 | 2020–2022 | ||
| Coelho Mary Theresa | Director | 5 | 2021–2024 | ||
| Romano Sarah | Officer | Chief Financial Officer | 13 | 2022–2025 | |
| Hoffman David Andrew | Director | 2 | 2022–2023 | ||
| KHOSLA CHAITAN PHD | Director | 3 | 2024 | ||
| Syage Jack | Director; Director,Officer | President & COO | 3 | 2024–2026 | |
| Ramdeen Timothy R. | Director | 1 | 2024 | ||
| Corbett Eric | Director | 1 | 2025 | ||
| Paolone Richard | Director,Officer | Interim CEO | 1 | 2025 | |
| Uppal Manpreet | Director | 2 | 2025–2026 | ||
| Pursglove Geordan Garrett | Director | 2 | 2025–2026 | ||
| Sawyer Jason David | Director; Director,Officer | Chief Executive Officer | 3 | 2025–2026 | |
| Skowron Anna | Officer | Interim CFO | 2 | 2025 |
Everyone who filed an insider report for this company, from the SEC’s Insider Transactions Data Sets (2006 on). Person pages are matched by name and state only.
Private offerings before or after (Form D)
| First filed | Issuer | Industry | Offering | Sold | Investors | Filings |
|---|---|---|---|---|---|---|
| 2026-07-15 | GridAI Technologies Corp. | Pharmaceuticals | $8,500,000 | $8,500,000 | 6 | 1 |
| 2026-05-27 | GridAI Technologies Corp. | Pharmaceuticals | $2,540,000 | $2,540,000 | 4 | 1 |
| 2026-05-27 | GridAI Technologies Corp. | Pharmaceuticals | $5,250,000 | $5,250,000 | 4 | 1 |
| 2025-08-18 | Entero Therapeutics, Inc. | Biotechnology | $3,025,000 | $3,025,000 | 3 | 1 |
| 2023-09-21 | First Wave BioPharma, Inc. | Biotechnology | $1,470,509 | $1,470,509 | 1 | 1 |
| 2023-06-28 | First Wave BioPharma, Inc. | Biotechnology | $431,083 | $431,083 | 1 | 1 |
| 2023-03-23 | First Wave BioPharma, Inc. | Biotechnology | $4,000,001 | $4,000,001 | 1 | 1 |
| 2022-12-01 | First Wave BioPharma, Inc. | Biotechnology | $2,500,001 | $2,500,001 | 1 | 1 |
| 2022-07-26 | First Wave BioPharma, Inc. | Biotechnology | $300,000 | $300,000 | 2 | 1 |
| 2020-07-31 | AzurRx BioPharma, Inc. | Biotechnology | $22,800,000 | $22,426,890 | 177 | 1 |
| 2020-01-17 | AzurRx BioPharma, Inc. | Biotechnology | $8,000,000 | $6,904,000 | 70 | 1 |
| 2019-03-01 | AzurRx BioPharma, Inc. | Biotechnology | $2,000,000 | $2,000,000 | 1 | 1 |
| 2017-06-15 | AzurRx BioPharma, Inc. | Biotechnology | $5,000,000 | $5,000,000 | 27 | 1 |
| 2017-04-21 | AzurRx BioPharma, Inc. | Biotechnology | $1,000,000 | $1,000,000 | 1 | 1 |
| 2016-04-11 | AzurRx BioPharma, Inc. | Biotechnology | $12,000,000 | $635,000 | 4 | 1 |
| 2014-11-03 | AzurRx BioPharma, Inc. | Biotechnology | $7,000,000 | $284,000 | 3 | 1 |
| 2014-04-02 | BioPharma d'Azur, Inc. | Biotechnology | $1,020,250 | $385,000 | 4 | 1 |
Data: SEC EDGAR. The quarterly full index (every S-1, S-1/A, F-1 and F-1/A since 1993, with the pricing prospectus, notice of effectiveness and withdrawal request of each registrant) and the company submissions data (SIC, state of incorporation, address, EIN, tickers, former names). Company details are what EDGAR holds today, not at the time of the filing.